The CK2 inhibitor CX-4945 exhibits anticancer activity by down-regulation of PI3K/Akt, p21 and HIF-1α and by that affects the transcriptional regulation of factors involved in cancer proliferation, angiogenesis and pro-inflammatory cytokine production. This evidence concerns the gene AKT1 and cancer.